February 15, 2018
ARLINGTON, Va. — Following the Drug Enforcement Administration’s (DEA) announcement yesterday regarding a new assessment tool for controlled substance orders, Healthcare Distribution Alliance (HDA) President and CEO John M. Gray issued the following statement.
“HDA commends the DEA for this positive step forward and welcomes the increased level of transparency in our collective efforts to combat the opioid epidemic. We have long advocated for the creation of new tools and enhanced information sharing between the DEA and industry, and this new assessment appears to reveal one aspect of much needed insight, specifically at the individual pharmacy level.
“We hope this is the first of many steps toward more strategic and tactical use of ARCOS data between the DEA and HDA member distributors. We look forward to working with the DEA as this tool is incorporated into ongoing monitoring efforts and encourage continued collaboration among DEA, other enforcement agencies and industry to enhance compliance and enforcement.”
The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s non-profit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.